Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Embecta Corp.EMBC · Entity 5950 | VP, CAO & Corp. Controller | November 26, 2023 | November 28, 2023 |
| TrueBlue, Inc.TBI · Entity 5919 | SVP, Chief Accounting Officer | January 12, 2026 | January 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Embecta Corp.
Report date November 26, 2023 · Filed November 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,054 |
Ending reported balance
After 2023-11-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-11-26 · Grant · Acquired 13,723 · Balance 21,946 Row 2 · 2023-11-26 · Tax withholding · Disposed 892 · Balance 21,054 F1: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units as previously reported on Table I. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units as previously reported on Table I.
TrueBlue, Inc.
Report date January 12, 2026 · Filed January 27, 2026
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CANTEL MEDICAL CORP
Report date June 02, 2021 · Filed June 02, 2021
Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Disposition to issuer · Disposed 12,216 · Balance 0 F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration").
F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 26, 2023 Filed Nov 28, 2023 20:09 UTC | Embecta Corp. EMBC · Entity 5950 | Tax withholdingCommon Stock | 892 | $17.49 | $15,601.08 |
DisclosureSEC source: 0000947871-23-001110 · ownership.xml · nonDerivative · entry 2 Capone Brian · CIK 0001709762 · VP, CAO & Corp. Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,054 F1 · shares: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units as previously reported on Table I. Read SEC document |
| November 26, 2023 Filed Nov 28, 2023 20:09 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 13,723 | $0.00 | $0.00 |
DisclosureSEC source: 0000947871-23-001110 · ownership.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · VP, CAO & Corp. Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,946 Read SEC document |
| November 26, 2022 Filed Nov 29, 2022 17:10 UTC | Embecta Corp. EMBC · Entity 5950 | Tax withholdingCommon Stock | 417 | $33.04 | $13,777.68 |
DisclosureSEC source: 0001209191-22-058964 · doc4.xml · nonDerivative · entry 2 Capone Brian · CIK 0001709762 · VP, CAO & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,223 F1 · shares: Represents shares withheld for payment of withholding taxes in connection with the vesting of restricted stock units as previously reported on Table I. Read SEC document |
| November 26, 2022 Filed Nov 29, 2022 17:10 UTC | Embecta Corp. EMBC · Entity 5950 | GrantCommon Stock | 4,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058964 · doc4.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · VP, CAO & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,640 Read SEC document |
| April 01, 2022 Filed May 12, 2022 18:29 UTC | Embecta Corp. EMBC · Entity 5950 | OtherStock Appreciation Rights · Derivative | 26,044 | $0.00 Strike: $28.31 | $0.00 |
DisclosureSEC source: 0001209191-22-028632 · doc4.xml · derivative · entry 2 Capone Brian · CIK 0001709762 · VP, CAO & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,044 Underlying: Common Stock · 26,044 shares Expires 2031-11-26 F2 · shares: These Stock Appreciation Rights ("SARs") were received by the reporting person when he was employed by BD and were later converted to Embecta SARs in connection with Embecta's spinoff from BD on April 1, 2022. F3 · derivative.exercise_date: The SARs vest in four annual installments beginning November 26, 2022. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 17:23 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Disposition to issuerCommon Stock, par value $.10 per share | 12,216 | $80.59 | $984,487.44 |
DisclosureSEC source: 0001104659-21-075845 · tm2118222-5_4seq1.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · kind: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. F1 · shares: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · shares: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. F1 · price: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2 · price: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. Read SEC document |
| October 10, 2020 Filed Oct 13, 2020 16:06 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Tax withholdingCommon Stock, par value $0.10 per share | 503 | $47.36 | $23,822.08 |
DisclosureSEC source: 0000019446-20-000090 · wf-form4_160261956198754.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,216 F1 · shares: This represents shares withheld for taxes attributable to vesting of time-based RSUs that vested on 10/10/2020. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 14:30 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | GrantCommon Stock, par value $0.10 per share | 7,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-20-000079 · wf-form4_160226823114827.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,719 F1 · shares: This represents time-based Restricted Stock Units granted on 10/7/20 that vest in three equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| July 13, 2020 Filed Jul 14, 2020 14:51 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | SaleCommon Stock, par value $0.10 per share | 300 | $44.14 | $13,240.50 |
DisclosureSEC source: 0000019446-20-000035 · wf-form4_159475265544538.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,106 Read SEC document |
| July 13, 2020 Filed Jul 15, 2020 14:17 UTC Amendment | CANTEL MEDICAL CORP CMD · Entity 138805 | SaleCommon Stock, par value $0.10 per share | 300 | $46.14 | $13,840.50 |
DisclosureSEC source: 0000019446-20-000036 · wf-form4a_159483702983835.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,106 F1 · price: This form has been amended to correct the price of the disposed securities as a result of an administrative error. Read SEC document |
| April 17, 2020 Filed Sep 9, 2020 20:07 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Tax withholdingCommon Stock, par value $0.10 per share | 172 | $28.23 | $4,855.56 |
DisclosureSEC source: 0000019446-20-000068 · wf-form5_159969643213646.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,934 F1 · shares: This represents shares withheld for taxes attributable to vesting of time-based RSAs that vested on 4/17/2020. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 11:18 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Tax withholdingCommon Stock, par value $0.10 per share | 276 | $68.89 | $19,013.64 |
DisclosureSEC source: 0000019446-19-000060 · edgar.xml · nonDerivative · entry 2 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,406 F2 · shares: This represents shares withheld for taxes attributable to the vesting of RSUs on 10/10/19. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 11:18 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | GrantCommon Stock, par value $0.10 per share | 2,180 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-19-000060 · edgar.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,682 F1 · shares: This represents time-based Restricted Stock Units (RSUs) granted on 10/10/19 that vest in three equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| April 17, 2019 Filed Apr 24, 2019 16:43 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Tax withholdingCommon Stock, par value $0.10 per share | 172 | $67.81 | $11,663.32 |
DisclosureSEC source: 0000019446-19-000022 · edgar.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,502 Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 10:33 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | SaleCommon Stock, par value $0.10 per share | 70 | $66.09 | $4,626.62 |
DisclosureSEC source: 0000019446-19-000017 · edgar.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,674 Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 16:03 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Tax withholdingCommon Stock, par value $0.10 per share | 124 | $88.42 | $10,964.08 |
DisclosureSEC source: 0000019446-18-000056 · edgar.xml · nonDerivative · entry 3 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,744 F3 · shares: This represents shares withheld for taxes attributable to the vesting of (i) time-based RSUs that vested on 10/10/18 and (ii) performance-based RSUs that vested on 10/10/18. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 16:03 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | GrantCommon Stock, par value $0.10 per share | 280 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-18-000056 · edgar.xml · nonDerivative · entry 2 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,868 F2 · shares: This represents a performance-based RSU granted on 10/10/17, as adjusted based on the Company's sales performance during the fiscal year ended July 31, 2018. One-third of these RSUs (as adjusted) vested on 10/10/18 and the balance of these RSUs are now time-based, vesting in two equal annual installments on 10/10/19 and 10/10/20. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 16:03 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | GrantCommon Stock, par value $0.10 per share | 1,445 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-18-000056 · edgar.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · SVP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,588 F1 · shares: This represents time-based Restricted Stock Units (RSUs) granted on 10/10/18 that vest in three equal annual installments commencing on the first anniversary of the grant date. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 14:19 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | Tax withholdingCommon Stock, par value $0.10 per share | 173 | $113.42 | $19,621.66 |
DisclosureSEC source: 0000019446-18-000023 · edgar.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · VP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,123 Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 14:14 UTC | CANTEL MEDICAL CORP CMD · Entity 138805 | GrantCommon Stock, par value $0.10 per share | 895 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-17-000042 · edgar.xml · nonDerivative · entry 1 Capone Brian · CIK 0001709762 · VP and Princ. Accounting Ofr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,296 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.